The vaccine to be produced in the United Arab Emirates is called Hayat-Vax and is the same vaccine developed by Chinese pharmaceutical giant Sinopharm China National Biotec Group (CNBG). Approved by the Emirates authorities and available free of charge to all residents of the U.A.E. The agreement is part of the "Life sciences and vaccine production in the United Arab Emirates'. by Group 42 (G42) of the United Arab Emirates - the leading Abu Dhabi-based company in Artificial Intelligence and Cloud computing - and China's CNBG (Sinopharm). The project was announced yesterday, Sunday 28 March, at a ceremony held in Abu Dhabi in the presence of His Highness Sheikh Abdullah bin Zayed Al Nahyan, Minister of Foreign Affairs and International Cooperation, and Chinese Foreign Minister Wang Yi. "The UAE and China today inaugurated a new chapter in their historic and distinguished relations, entitled Strategic partnership for humanity“, Sheikh Abdullah said. "Today we celebrate the significant milestones achieved by our strategic partnership at all levels," added the UAE's top diplomat, specifying that the dividends of this significant project will be reaped, not only by the UAE and China, but by the world at large. 

The ceremony began with a short video on cooperation between the UAE and China during the COVID-19 crisis."We are making great step forward in the global battle against COVID-19 - Liu Jingzhen, President of Sinopharm, said. - and this pioneering project is the result of close cooperation and strategic partnership between the UAE and China and their leading efforts to combat this crisis". "The UAE has pioneered the registration and commercial production of Sinopharm's vaccine, embodying the significant efforts made by the two friendly nations to recover from the crisis. This project will play a significant role in addressing the COVID-19 pandemic in the UAE, the Arab region and the world at large." 

According to Peng Xiao, CEO of G42, the new project will 'revolutionise the life sciences industry in the region in the coming years' and the new technologies will enable both parties to respond quickly to the growing demand for the vaccine both locally and internationally.

The start of production of the first COVID-19 vaccine production line on Emirati territory is a further U.A.E. commitment to overcoming the pandemic through a collaborative effort put in place last year with the signing of a clinical cooperation agreement between Sinopharm China National Biotec Group (CNBG) and Group 42 (G42) for the first phase III clinical trial of China's inactivated COVID-19 vaccine. "G42 and CNBG have achieved significant results since 2020 due to their common vision and values," Peng Xiao said.

"We are continuing the efforts we started at the beginning of the COVID-19 crisis - stressed Sheikh Abdullah - The joint project is an added value to the international efforts made in the face of the COVID-19 crisis that has challenged everyday life around the world The UAE believes in the importance of collective action and concerted efforts in combating such crises. We believe that we should work collectively and move forward with our efforts to stem the fallout from the crisis and to work towards ensuring the security and stability of all the peoples of the world."

(Photo: Emirates News Agency)


Please enter your comment!
Please enter your name here